Comments on: Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

Comments on: Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer https://thegbm.com/roches-divarasib-demonstrated-best-in-class-efficacy-advancing-the-standard-of-care-in-previously-treated-kras-g12c-mutated-lung-cancer/ Business news, opinion, reviews, interviews Sun, 25 Oct 2026 15:30:00 +0000 hourly 1 https://wordpress.org/?v=7.1.3